Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
Patent Number: 7,399,751
This is a patent with priority in 1999 describing the use of genetically modified Sertoli cells for immune protection of implanted cells AND the use of the Sertoli cells themselves as the vector...genetic engineer with any gene is covered.
This patent is part of the Canadian company Sernova's (CDNX:SVA.V) potent intellectual property portfolio covering the space of xenotransplantation in general and specifically treatment of diabetes. Sernova has demonstrated clinical proof of concept for its core technology and is working its way through the FDA regulatory process for its lead candidate Sertolin.
We at StemCellPatents.com believe Sernova is an "undiscovered jewel" given that it owns IP rights on the sertoli cell itself, as well, its scientific founder, Dr. David White has a track record of success, including developing the field of xenotransplantation by "inventing" the DAF transgenic pig.
View this patent on the USPTO website.
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.